SOURCE: Auriga Laboratories, Inc.

January 07, 2008 08:45 ET

Auriga Laboratories Signs Co-Promotion Agreement With MiddleBrook Pharmaceuticals for Keflex® 750 mg

LOS ANGELES, CA--(Marketwire - January 7, 2008) - Auriga Laboratories, Inc. (OTCBB: ARGA), a specialty pharmaceutical company, announced today the signing of a co-promotion agreement with MiddleBrook Pharmaceuticals, Inc., pursuant to which Auriga will co-promote Keflex® 750 mg capsules (cephalexin capsules, USP), to Primary Care Specialists in the U.S.

Cephalexin, the generic form of Keflex, is the third most prescribed outpatient antibiotic in the U.S., with approximately 25 million prescriptions written annually. Cephalexin is the number-one most prescribed oral cephalosporin antibiotic and is also the number-one recommended oral antibiotic therapy for uncomplicated skin and skin structure infections.

The co-promotion will begin during the 1st Quarter of 2008. "This agreement solidifies Auriga's commitment to enhance our product portfolio. Currently, over 50% of cephalexin prescriptions are written by Primary Care Specialists which makes Keflex® 750 mg a highly synergistic addition to Auriga's current primary care promotional efforts," said Philip S. Pesin, CEO of Auriga.

About Keflex:

Keflex (cephalexin capsules, USP) is a first-generation cephalosporin antibiotic shown to be active against strains of both gram-positive and gram-negative aerobes in vitro and in clinical infections. Keflex is indicated for treatment of the following infections: respiratory tract infections, otitis media, skin and skin structure infections, bone infections, and genitourinary tract infections. More information on Keflex and prescribing information are available at www.middlebrookpharma.com/products_antibiotics/keflex_antibiotics.aspx.

About Auriga Laboratories™

Auriga Laboratories is a specialty pharmaceutical company building an industry changing commission based-sales model. The company's high-growth business model combines driving revenues through a variable cost commission-based sales structure, acquisition of proven brand names, introduction of new brands, and a strategic development pipeline, all of which designed to enhance its growing direct relationships with physicians nationwide. Auriga's exclusive prescription and over-the-counter product portfolio includes Aquoral™ for the treatment of Xerostomia, Akurza™, Xyralid™, Zytopic™, and Coraz™ dermatology products, and the Zinx™ respiratory product line.

Forward-Looking Statements

The information contained herein includes forward-looking statements. These statements relate to future events or to the company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause its actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to its operations, results of operations, growth strategy and liquidity. The company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although the company believes that its expectations are based on reasonable assumptions, it can give no assurance that its goals will be achieved and these statements will prove to be accurate. Important factors could cause actual results to differ materially from those included in the forward-looking statements.